Latest Strategy Changes News

Asara Resources (ASX:AS1) is pushing ahead at its Kada Gold Project in Guinea’s prolific Siguiri Basin, boasting a 923,000-ounce gold resource and launching expansive 2026 drilling campaigns aimed at significantly growing both Indicated and Inferred categories.

QEM Limited is set to acquire two past-producing critical mineral projects in Idaho, backed by a $2.645 million placement. The move aligns with US efforts to secure domestic supplies of fluorspar, tungsten, and niobium amid global supply chain vulnerabilities.

Scott Technology delivered a solid HY26 with 7% EBITDA growth to $13 million, driven by strong performances in Materials Handling and Mining, offsetting softness in Protein and Appliances. Forward work rose to $177 million, underpinning expectations for a stronger second half despite geopolitical uncertainties.

Andromeda Metals has wrapped up the Early Works phase at its Great White Project, setting the stage for construction and trimming the equity funding needed for the next development stage to about $40 million.

Marquee Resources (ASX:MQR) has secured a non-exclusive R&D patent licence with Oak Ridge National Laboratory, granting access to NEAREST technology tailored for clay-rich rare earth deposits like Redlings in WA. This partnership could reshape processing efficiency and environmental impact for Marquee’s significant inferred resource.

Australian Unity Office Fund has secured Foreign Investment Review Board approval for the $40 million sale of its Brisbane office tower, setting the stage for a pivotal unitholder meeting to approve the sale, delisting, and wind-up of the fund.

XRF Scientific posted a 13.8% jump in March quarter revenue to $15.8 million, led by strong international sales and new product shipments. The newly operational India office marks a strategic expansion, setting the stage for further growth.

Noxopharm appoints its Chief Scientific Officer Dr Olivier Laczka as CEO, aiming to capitalise on recent clinical successes and expand the Sofra™ technology’s reach in autoimmune and oncology markets.

Immutep Limited has won FDA Orphan Drug Designation for its immunotherapy eftilagimod alfa in treating soft tissue sarcoma, opening regulatory incentives and potential market exclusivity. This follows encouraging Phase II data despite recent Phase III trial setbacks.

Riversgold Limited has reported standout assay results from 31 drill holes at its Northern Zone Gold Project, including a spectacular 71 g/t gold intercept. The campaign expands the shallow gold mineralisation footprint, supporting imminent mining lease conversion and a funding agreement with MEGA Resources.

Larvotto Resources is progressing the Hillgrove Antimony-Gold Project on time and budget, aiming for mid-2026 production amid rising strategic demand for antimony. The project benefits from grid power, ongoing drilling success, and government support for critical minerals.

WhiteHawk Limited has raised A$1.5 million through a share placement to fund integration and growth of its newly acquired Quixxi Clarity AI platform, marking a strategic push into the AI governance market.